NCT06085521View on ClinicalTrials.gov

A Study of LNK01001 Capsule in Patients With Moderate to Severe Atopic Dermatitis

PHASE2CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

January 26, 2022

Primary Completion Date

June 14, 2023

Study Completion Date

June 14, 2023

Conditions
Atopic Dermatitis
Interventions
DRUG

LNK01001 Dose A

Capsules taken orally

DRUG

LNK01001 Dose B

Capsules taken orally

DRUG

placebo

Capsules taken orally

Trial Locations (1)

Unknown

Jianzhong Zhang, Beijing

Sponsors
All Listed Sponsors
lead

Lynk Pharmaceuticals Co., Ltd

INDUSTRY

NCT06085521 - A Study of LNK01001 Capsule in Patients With Moderate to Severe Atopic Dermatitis | Biotech Hunter | Biotech Hunter